Schizophrenia: all 3,539 studies

Page 10 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01423916Phase 1Results posted
• Electronic Decision Support Systems for Smokers With Severe Mental IllnessCompletedNCT01412866Not applicableResults posted
• A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With SchizophreniaCompletedNCT01412060Phase 3Results posted
• Risperidone and Desipramine in Alcohol Use and SchizophreniaCompletedNCT01411085Phase 2Results posted
• Improving Outcomes for Individuals With Serious Mental Illness and DiabetesCompletedNCT01410357Not applicableResults posted
• Nicotinic Receptors and SchizophreniaCompletedNCT01400477Phase 2Results posted
• Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With SchizophreniaCompletedNCT01397786Phase 3Results posted
• Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute SchizophreniaCompletedNCT01396421Phase 3Results posted
• Efficacy Study of OPC-34712 in Adults With Acute SchizophreniaCompletedNCT01393613Phase 3Results posted
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT01393600Phase 2Results posted
• Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia ParticipantsCompletedNCT01387542Phase 4Results posted
• Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaCompletedNCT01377233Phase 2Results posted
• Lifestyle Intervention for Weight Gain Management for Patients With SchizophreniaCompletedNCT01368406Not applicableResults posted
• Phase IIb-III Study of BL-1020 Small Molecule for SchizophreniaTerminatedNCT01363349Phase 2/3Results posted
• Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 YearsCompletedNCT01362439Phase 4Results posted
• A Study of Safety and Tolerability in Subjects With SchizophreniaCompletedNCT01354353Phase 1Results posted
• N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum PsychosisCompletedNCT01354132Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic PatientsCompletedNCT01348100Phase 1/2Results posted
• The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage SchizophreniaCompletedNCT01339858Phase 4Results posted
• Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With SchizophreniaCompletedNCT01338298Not applicableResults posted
• A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsTerminatedNCT01328093Phase 3Results posted
• An Integrated Program for the Treatment of First Episode of PsychosisCompletedNCT01321177Not applicableResults posted
• Nicotine Effects on Endophenotypes of SchizophreniaCompletedNCT01315002Not applicableResults posted
• Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?CompletedNCT01312272Not applicableResults posted
• A Study of LY2140023 in Patients With SchizophreniaTerminatedNCT01307800Phase 3Results posted
• A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired SubjectsCompletedNCT01299454Phase 1Results posted
• An Efficacy and Safety Study of Paliperidone Palmitate in Participants With SchizophreniaCompletedNCT01299389Phase 3Results posted
• Relapse Prevention Study in Patients With SchizophreniaCompletedNCT01291511Phase 3Results posted
• Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired SubjectsCompletedNCT01289080Phase 1Results posted
• Different Safety Profile of Risperidone and Paliperidone Extended-releaseCompletedNCT01284959Phase 4Results posted
• Efficacy of Repyflec Cognitive Remediation Group Training in SchizophreniaCompletedNCT01279070Phase 4Results posted
• Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) StudyCompletedNCT01269710Results posted
• Reducing Internalized Stigma in People With Serious Mental IllnessCompletedNCT01259427Phase 2Results posted
• Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)CompletedNCT01244828Phase 3Results posted
• Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of SchizophreniaCompletedNCT01242371Not applicableResults posted
• A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in SchizophreniaCompletedNCT01232790Not applicableResults posted
• Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable SchizophreniaCompletedNCT01213836Phase 4Results posted
• Nicotine and Sensorimotor Replacement for Smoking in Smokers With SchizophreniaCompletedNCT01213524Phase 2Results posted
• Switching to Iloperidone From Other Antipsychotics in SchizophreniaCompletedNCT01207414Phase 4Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)CompletedNCT01206517Phase 1Results posted
• fMRI Cholinergic Mechanisms in SchizophreniaCompletedNCT01191827Results posted
• Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)CompletedNCT01190267Phase 3Results posted
• Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)CompletedNCT01190254Phase 3Results posted
• Salsalate for Insulin Resistance in SchizophreniaCompletedNCT01182727Not applicableResults posted
• Metformin for Weight Loss in SchizophreniaTerminatedNCT01177709Not applicableResults posted
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of SchizophreniaCompletedNCT01175135Phase 2Results posted
• Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on LurasidoneCompletedNCT01173874Phase 3Results posted
• 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and IncarceratedCompletedNCT01157351Phase 4Results posted
• Efficacy & Safety Study of Oral Aripiprazole in Adolescents With SchizophreniaCompletedNCT01149655Phase 3Results posted
• A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective DisorderCompletedNCT01143090Phase 3Results posted
• A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic AgentsCompletedNCT01143077Phase 3Results posted
• Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)CompletedNCT01142596Phase 3Results posted
• An Open Trial of Cysteamine Treatment in SchizophreniaTerminatedNCT01139125Not applicableResults posted
• A Comparison of Long-acting Injectable Medications for SchizophreniaCompletedNCT01136772Phase 4Results posted
• An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With SchizophreniaCompletedNCT01129882Phase 3Results posted
• A Study in Schizophrenic PatientsTerminatedNCT01125358Phase 2Results posted
• Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.TerminatedNCT01122927Phase 3Results posted
• Varenicline and Smoking Cessation in SchizophreniaCompletedNCT01111149Phase 2Results posted
• Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic PatientsCompletedNCT01109147Phase 4Results posted
• Long-term Study of Cariprazine in Patients With SchizophreniaCompletedNCT01104792Phase 3Results posted
• Safety and Efficacy of Cariprazine in SchizophreniaCompletedNCT01104779Phase 3Results posted
• Safety and Efficacy of Cariprazine in Patients With SchizophreniaCompletedNCT01104766Phase 3Results posted
• A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)CompletedNCT01101464Phase 2Results posted
• Effects of Galantamine on CognitionCompletedNCT01100775Phase 2Results posted
• 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)CompletedNCT01098110Phase 3Results posted
• Effects of Pravastatin on Cholesterol, Inflammation and Cognition in SchizophreniaCompletedNCT01082588Phase 4Results posted
• Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsCompletedNCT01081769Phase 3Results posted
• Cerebellar rTMS for the Treatment of Schizophrenic PatientsCompletedNCT01072617Not applicableResults posted
• A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox CapsuleCompletedNCT01053429Results posted
• A Study of LY2140023 in Schizophrenia Patients With Prominent Negative SymptomsCompletedNCT01052103Phase 2Results posted
• A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in ChildrenCompletedNCT01050582Phase 4Results posted
• DECIFER: Depression and Citalopram In First Episode RecoveryCompletedNCT01041274Phase 4Results posted
• Antidepressant Controlled Trial for Negative Symptoms in SchizophreniaCompletedNCT01032083Phase 4Results posted
• Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of SchizophreniaCompletedNCT01029769Not applicableResults posted
• Oxytocin Treatment of SchizophreniaCompletedNCT01028677Not applicableResults posted
• Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in SchizophreniaCompletedNCT01012167Phase 2Results posted
• A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With RisperidoneCompletedNCT01010776Phase 4Results posted
• Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in SchizophreniaCompletedNCT01010477Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of GSK239512 in SchizophreniaCompletedNCT01009060Phase 2Results posted
• An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With SchizophreniaCompletedNCT01009047Phase 3Results posted
• Vitamin D Supplementation in Psychiatric IllnessesCompletedNCT01004354Not applicableResults posted
• Oral Aripiprazole Open-Label Rollover StudyCompletedNCT01001702Phase 3Results posted
• Remediation of Working Memory in SchizophreniaCompletedNCT00995553Not applicableResults posted
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective DisorderCompletedNCT00992407Phase 4Results posted
• Study in Adolescents With Schizophrenia or Bipolar DisorderCompletedNCT00982020Phase 4Results posted
• Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With SchizophreniaCompletedNCT00981526Phase 4Results posted
• Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin ElevationTerminatedNCT00975611Phase 4Results posted
• A Study of Olanzapine in Patients With SchizophreniaCompletedNCT00970281Phase 3Results posted
• D-cycloserine Augmentation of Cognitive Remediation in SchizophreniaCompletedNCT00963924Not applicableResults posted
• Smoking Cessation for Veterans With Severe and Persistent Mental IllnessCompletedNCT00960375Phase 2/3Results posted
• Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute SchizophreniaCompletedNCT00954122Phase 4Results posted
• Nicotinic Receptors and SchizophreniaCompletedNCT00952393Phase 1Results posted
• 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 YearsTerminatedNCT00946985Phase 4Results posted
• Cannabis and Schizophrenia: Self-Medication and Agonist TreatmentCompletedNCT00946348Phase 1Results posted
• Mindfulness Meditation as a Rehabilitation Strategy for Persons With SchizophreniaCompletedNCT00936351Not applicableResults posted
• A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy ControlsTerminatedNCT00934635Phase 4Results posted
• Oculomotor and Spatial Cognition Deficits in SchizophreniaTerminatedNCT00931996Not applicableResults posted
• Neurophysiological Targets for Cognitive Training in SchizophreniaCompletedNCT00923078Not applicableResults posted
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative SymptomsCompletedNCT00922272Phase 2Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute SchizophreniaCompletedNCT00905307Phase 2Results posted

← Schizophrenia overview